Interleukin-1 beta genotype and circulating levels in cancer patients: Metastatic status and pain perception

• Type: Article in International Scientific Journal
• Date: 2014

Authors

Ana Oliveira (Author) Other; Ricardo Jorge Dinis Oliveira (Author) FMUP; Augusto Nogueira (Author) Other; Ferraz Goncalves (Author) Other; Paula Silva (Author) Other; Claudia Vieira (Author) Other; Ricardo Silvestre (Author) Other; Felix Carvalho (Author) FFUP; Rui Medeiros (Author) Other

Journal

Title: Clinical Biochemistry

Vol. 47

Pages: 1209-1213

ISSN: 0009-9120

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 23 Citations

Scopus - 25 Citations

Scientific classification

FOS: Engineering and technology > Medical engineering

Other information

Authenticus ID: P-009-T4A

DOI: 10.1016/j.clinbiochem.2014.04.009

Abstract (EN): Objectives: Proinflammatory cytokines released during inflammation can cause hyperexcitability in pain transmission neurons, leading to hyperalgesia and allodynia. Polymorphisms in interleukin 1 (IL-1) family of genes (IL1A, IL1B) and in IL-1 receptor antagonist (IL-1Ra, coded by IL1RN) may therefore induce alterations in cytokine levels/effects and pain related response. Our purpose was to investigate the influence of polymorphisms in IL1A/B/RN on cytokine serum levels and its correlation with pain intensity, performance status, adverse effects, metastases and breakthrough pain in Caucasian cancer patients. Design and methods: SerumIL-1 alpha/beta levels of 74 cancer patients were measured by competitive enzyme immunosorbent assay. All patients were also genotyped for the polymorphisms in IL1A (rs17561), IL1B (rs1143634) and IL1RN (rs419598) with Real-Time PCR. Results were then correlated to the appearance of bone or CNS metastases and several pain-related parameters. Results: IL-1 beta rs1143634 homozygous for T allele were associated with lower levels of IL1-beta (p = 0.032, Mann-Whitney test) and presented a trend for lower levels of pain (p = 0.06, Fisher's Exact Test). Also, IL1-beta levels were related with cancer onset status, since a four-fold increase probability of metastatic disease was observed in high IL-1 beta individuals (OR=4.074, p=0.010, Pearson chi(2) test). Among the female patients presenting metastatic disease and carriers of the TT genotype we observed a trend to lower levels of IL1-beta (p = 0.053, Pearson chi(2) test). Conclusions: Our results indicate that genetic variation at IL1-beta gene may influence serum levels of IL1-beta, with proportional consequences in cancer-related pain.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 5